KRAKOW, Poland, July 31, 2025 / Biotech Newswire / -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focused on novel therapies targeting emerging oncology indications, announces the publication of data from its proprietary ONCO Prime target discovery platform in the peer-reviewed Scientific Reports journal, part of Nature Portfolio. The manuscript is entitled “Integrated transcriptomic and functional modeling reveals AKT and mTOR synergy in colorectal cancer” and is now available online on the Scientific Reports website and www.ryvu.com.
Krzysztof Brzozka, PhD, Chief Scientific Officer of Ryvu Therapeutics, said: "We are honored to have data from our ONCO Prime platform published and reviewed by expert peers in Nature Scientific Reports. The manuscript highlights the unique potential of our patient-derived primary cell cultures to reflect more accurately the complexity of patient tumors and therefore act as an ideal medium for novel therapeutic target discovery. The publication on AKT and mTOR synergy in colorectal cancer is just one example of the broad potential of the ONCO Prime platform across multiple tumor types as we continue to expand the platform."
The publication focuses on the discovery of a synergistic therapeutic relationship between mTOR inhibition and AKT inhibition in colorectal cancer cells as one example of the potential of the ONCO Prime platform.
- Ryvu developed a drug discovery platform using patient-derived primary CRC cultures. Importantly, Ryvu’s engineered model and patient-derived cells reflect the complexity and heterogeneity of primary tumors, not observed with standard immortalized cell lines.
- High-throughput screening (HTS) of 4255 compounds identified 33 with selective efficacy against CRC cells, sparing normal, healthy epithelial cells.
- Among the tested combinations, everolimus (mTOR inhibitor) and uprosertib (AKT inhibitor) demonstrated promising synergy with favorable therapeutic window. This synergy might have been overlooked in traditional immortalized cell lines, highlighting the translational advantage of patient-derived systems.
- The integration of machine learning into the HTS pipeline significantly improved scalability, cost-efficiency, and predictive accuracy.
These findings underscore the potential of patient-derived materials combined with machine learning-enhanced drug discovery to advance personalized therapies. Specifically, mTOR-AKT inhibition emerges as a promising strategy for CRC treatment, paving the way for more effective and targeted therapeutic approaches.
Beyond the results published in this manuscript, the ONCO Prime platform has already led to the discovery of several other novel targets with therapeutic potential in CRC. These undisclosed, potential novel targets are currently being advanced through the drug discovery process at Ryvu. In addition, the ONCO Prime platform is expanding to other tumor types.
Scientific Reports is a peer-reviewed, open-access journal, part of Nature Portfolio, publishing original research across the natural sciences, psychology, medicine and engineering. From nature.com: “Scientific Reports is the 5th most-cited journal in the world, with more than 734,000 citations in 2023, and receives widespread attention in policy documents and the media.”
About Ryvu Therapeutics
Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel oncology therapies that address emerging targets in oncology. Internally discovered pipeline candidates at Ryvu use diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules and antibody-drug conjugates directed at kinases, synthetic lethality, and immuno-oncology targets.
Ryvu’s most advanced program is RVU120, a selective CDK8/CDK19 kinase inhibitor with the potential to treat hematological malignancies. RVU120 is currently in Phase II development (i) in combination with venetoclax for the treatment of patients with r/r AML – the RIVER-81 study, (ii) as a monotherapy for the treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS) – the REMARK study, (iii) as a monotherapy and in combination with ruxolitinib for the treatment of patients with myelofibrosis (MF) – the POTAMI-61 study. Dapolsertib (MEN1703, SEL24) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is currently being investigated in a Phase II study in diffuse large B-cell lymphoma (DLBCL) – the JASPIS-01 study. RVU305, a potentially best-in-class, brain-permeable PRMT5 inhibitor aiming to treat multiple solid tumors, is currently in IND/CTA-enabling studies. Ryvu Therapeutics is also engaged in oncology collaborations with BioNTech and Exelixis. Ryvu was founded in 2007 and is headquartered in Kraków, Poland. It is listed on the Warsaw Stock Exchange and is a component of the sWIG80 index.
Contact
Ryvu Therapeutics
Anna Wilk
+48 532 698 425
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Colorectal Neoplasms; MTOR Inhibitors; TOR Serine-Threonine Kinases; Ryvu Therapeutics; ONCO Prime; colorectal cancer (CRC); drug discovery; Scientific Reports; Nature Portfolio; AKT inhibition; high-throughput screening (HTS); everolimus; uprosertib; machine learning; predictive accuracy; personalized therapies; translational advantage; novel oncology therapies; synthetic lethality; immuno-oncology; RVU120; CDK8/CDK19 kinase inhibitor; RVU305; Kraków, Poland; Warsaw Stock Exchange
Source: Biotech Newswire